Sage Therapeutics: Oral treatment for Parkinson’s shows positive phase 2 results

Sage Therapeutics Inc. announced positive results from a phase 2 trial for an oral treatment that was linked to improvements in functioning, learning and memory in those with mild cognitive impairment from Parkinson’s disease.

Data on the first-in-class, positive allosteric modulator of the NMDA receptor, dubbed SAGE-718, were reported from the open label phase 2 PARADIGM study, part of the biopharmaceutical company’s early-stage trial platform to treat cognitive deficits across a range of brain disorders.

healio.com/news/neurology/2...

[Hidden]

Thank you for sharing trial info such as this!

[Hidden]

for PD

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

clinicaltrials.gov/ct2/show...

FoR Huntington's Disease (HD)

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

clinicaltrials.gov/ct2/show...